BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19563669)

  • 1. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
    Foster FM; Owens TW; Tanianis-Hughes J; Clarke RB; Brennan K; Bundred NJ; Streuli CH
    Breast Cancer Res; 2009; 11(3):R41. PubMed ID: 19563669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
    Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
    Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Bockbrader KM; Tan M; Sun Y
    Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP; Bonavida B
    Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
    Brady SW; Zhang J; Tsai MH; Yu D
    Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
    Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
    Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
    Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
    BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
    Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
    Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
    Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner.
    Stanculescu A; Bembinster LA; Borgen K; Bergamaschi A; Wiley E; Frasor J
    Horm Cancer; 2010 Jun; 1(3):127-35. PubMed ID: 21152357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
    Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).
    Rathore R; McCallum JE; Varghese E; Florea AM; Büsselberg D
    Apoptosis; 2017 Jul; 22(7):898-919. PubMed ID: 28424988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
    Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
    Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoprotective effects of IAPs revealed by a small molecule antagonist.
    Galbán S; Hwang C; Rumble JM; Oetjen KA; Wright CW; Boudreault A; Durkin J; Gillard JW; Jaquith JB; Morris SJ; Duckett CS
    Biochem J; 2009 Feb; 417(3):765-71. PubMed ID: 18851715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
    Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Saitou Y; Sugimoto K; Nakano T
    Oncol Rep; 2005 Nov; 14(5):1311-6. PubMed ID: 16211302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.